Kidney Week

Abstract: FR-PO0654

Health Care Resource Use and Economic Burden of ANCA-Associated Vasculitis in the United States

Session Information

• Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - ANCA/FSGS
  October 23, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Ibiloye, Elizabeth A., Amgen Inc, Thousand Oaks, California, United States

Elizabeth A. Ibiloye, PhD

• Ravipati, Prasanth, University of Nebraska Omaha, Omaha, Nebraska, United States

Prasanth Ravipati, MD

• Pham, Phuong, Amgen Inc, Thousand Oaks, California, United States

Phuong Pham, PhD

• Oh, Sam S., Amgen Inc, Thousand Oaks, California, United States

Sam S. Oh, PhD, MPH

• Banerjee, Shubhasree, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Shubhasree Banerjee, MD

• Bozeman, Alana M., Amgen Inc, Thousand Oaks, California, United States

Alana M. Bozeman, MD

• Kathe, Niranjan, Amgen Inc, Thousand Oaks, California, United States

Niranjan Kathe, PhD

Background

The ANCA-associated vasculitis (AAV) treatment landscape has evolved considerably in the past decade. We aimed to describe AAV healthcare resource use (HCRU) and economic burden using data from a large, nation-wide United States (US) claims database.

Methods

This descriptive retrospective cohort study examined US MarketScan® Commercial and Medicare Supplemental claims data (1/1/2016–1/31/2025) and included adults ≥18 years with AAV and ≥12 months continuous enrollment pre-index. The index date was the first qualifying AAV claim that met the AAV definition during the identification period (1/1/2017–1/31/2025). HCRU and costs were evaluated post-index, and patterns were assessed annually. Results were stratified into newly diagnosed or established AAV within the identification period.

Results

Among 4453 patients with AAV (59% female; mean age 54 years), 41% were newly diagnosed. Median (IQR) follow-up was 615 (304, 1079) days. HCRU and costs across all groups were highest for inpatient (IP) care, with means of 1.0 IP admission and 9.0 IP days per person per year (PPPY), and $56,400 in IP costs out of $111,000 in total costs PPPY; HCRU and costs were higher in patients with newly diagnosed vs established AAV (Figure). In patients with newly diagnosed AAV, all-cause and kidney-related HCRU and costs were highest in Year 1, with 1.9 all-cause IP admissions, 17.8 IP days, and $111,900 in IP costs PPPY (kidney-related: 1.1, 12.3, and $73,200, respectively), declining in Years 2 and 3.

Conclusion

HCRU and costs are substantial in AAV, particularly among patients with newly diagnosed disease during the first year post-diagnosis, a critical window marked by high HCRU and cost burden and intensive treatment.

Acknowledgment

This study was funded by Amgen Inc. Writing and editorial support were funded by Amgen Inc and provided by Danielle Ippolito, PhD (on behalf of Amgen Inc), and Rachel E. Gurlin, PhD, from Amgen Inc, under the direction of the authors.

Figure. All-cause and kidney-related HCRU and costs among patients with newly diagnosed or established AAV^a

Funding

• Commercial Support – Amgen Inc